WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.

Raccontata daforbes.comgizmodo.comsciencealert.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
gizmodo.com1 mesi fa

Can Ozempic Treat Alcoholism? Here's What You Should Know

A first Lancet RCT (26 weeks, n=100) found semaglutide reduced alcohol consumption and heavy drinking days vs placebo. The shared dopamine mechanism implies GLP-1s could address multiple addictions, reshaping Novo Nordisk's pipeline beyond obesity.

Leggi questa versione → originale
sciencealert.com1 mesi fa

One Weight Loss Strategy Is 5x More Effective Than Ozempic, Study Shows

Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people.

Leggi questa versione → originale

Timeline cronologica

  1. domenica 24 maggio 2026·forbes.com

    Employer Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Covered

    GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

  2. martedì 26 maggio 2026·gizmodo.com

    Ozempic Is Finally Turning the Tide Against Obesity, New Data Shows

    As the rate of GLP-1 prescriptions in the U.S. has risen, the obesity rate has dropped.

forbes.com1 mesi fa

Employer Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Covered

GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

Leggi questa versione → originale
  • giovedì 28 maggio 2026·sciencealert.com

    One Weight Loss Strategy Is 5x More Effective Than Ozempic, Study Shows

    Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people.

  • giovedì 28 maggio 2026·sciencealert.com

    Weight Loss on GLP-1 Drugs Linked to Lower Risk of Disease, Study Finds

    Does losing weight by taking GLP-1 drugs such as Ozempic and Wegovy actually improve your risk of other diseases associated with obesity? New research led by scientists at the…

  • venerdì 29 maggio 2026·gizmodo.com

    Can Ozempic Treat Alcoholism? Here's What You Should Know

    A recent trial is the latest to suggest that GLP-1s aren't just for treating diabetes and obesity.